Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD)
Childhood acute lymphoblastic leukemia (ALL) treatment is one of the 20th Century’s great cancer success stories. Today more than 90 percent of children with ALL become long-term survivors, compared to just 4 percent in 1962 when St. Jude opened its doors.
Stage set to determine if drugs called tyrosine kinase inhibitors will extend the lives of patients with the high-risk acute lymphoblastic leukemia subtype; pediatric clinical trial scheduled to open by early 2015. (Charles Mullighan, MBBS(Hons), MSc, MD)
Research from St. Jude Children’s Research Hospital, Memorial Sloan-Kettering Cancer Center and the University of Washington identifies a mutation that predisposes individuals to most common form of childhood leukemia. (Dr. Charles Mullighan)
A study led by St. Jude Children’s Research Hospital shows epigenetic changes that turn genes on and off are as unique as alterations in DNA and may be as important in causing the most common childhood cancer. (Dr. Charles Mullighan)
The Pediatric Cancer Genome Project uncovers the genetic mutations that give rise to cancer.
St. Jude Children’s Research Hospital scientists lead a study that finds new genetic defects in high-risk childhood leukemia subtypes with chromosomal loss and evidence that some patients have an inherited cancer syndrome. (Charles Mullighan, MBBS(Hons), MSc, MD)
Scientist at St. Jude is recipient of 2012 Meyenburg Cancer Research Award. (Dr. Charles Mullighan)
Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer. (Charles Mullighan, MD)
Pediatric Cancer Genome Project scientists begin to uncover treasures.
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project discovers genetic connection linking two cancers that is likely to expand treatments for patients who currently have poor prognoses. (Dr. Charles Mullighan)
The effort led by St. Jude Children’s Research Hospital scientists identified the gene as a potential marker of relapse risk and involved the most comprehensive search yet for genomic changes in relapsed childhood acute lymphoblastic leukemia
St. Jude scientists identify a completely new and deadly subtype of leukemia that arises from early T-cell precursors. The discovery allows early detection and therapeutic intervention to improve the outcome for children with this form of drug-resistant leukemia.
Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.
Long ago, doctors and researchers at St. Jude started collecting their own piece of history, with help from the hospital’s patients. The patients’ contribution to history was even more valuable than the most pristine Mantle card: They donated samples that could help researchers find cures for catastrophic childhood diseases.
Charles Mullighan, MD, PhD, an assistant member in the Pathology Department at St. Jude Children’s Research Hospital, has been named a 2009 Pew Scholar in the Biomedical Sciences. He is the fourth St. Jude scientist honored.
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death.
Results of collaborative study could lead to development of new diagnostic tools and a new therapeutic target in high-risk disease.
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
Scientists have identified genetic mutations that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).
Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). Although the researchers caution that further research is needed to determine how changes in the gene, called IKZF1 or IKAROS, lead to leukemia relapse, the findings are likely to provide the basis for future diagnostic tests to assess the risk of treatment failure.
Scientists at St. Jude have identified distinctive genetic changes that cause relapse in children with acute lymphoblastic leukemia (ALL).
When James Downing walked into his pathology lab one day, postdoctoral fellow Charles Mullighan was staring at his computer screen, transfixed. "He was literally white," Downing recalls. "You are not going to believe what I just found," Mullighan said.